G1 Therapeutics, Inc. (NASDAQ:GTHX) to Post Q2 2024 Earnings of ($0.18) Per Share, Wedbush Forecasts

G1 Therapeutics, Inc. (NASDAQ:GTHX) – Equities research analysts at Wedbush boosted their Q2 2024 earnings estimates for shares of G1 Therapeutics in a report issued on Wednesday, May 1st. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.18) per share for the quarter, up from their previous estimate of ($0.20). Wedbush has a “Outperform” rating and a $5.00 price target on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.59) per share. Wedbush also issued estimates for G1 Therapeutics’ Q3 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.64) EPS, Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.49) EPS and FY2026 earnings at ($0.37) EPS.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The business had revenue of $14.48 million during the quarter, compared to the consensus estimate of $15.21 million. G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. During the same period last year, the company earned ($0.53) EPS.

GTHX has been the topic of a number of other reports. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 target price on shares of G1 Therapeutics in a research report on Wednesday, May 1st. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of G1 Therapeutics in a research note on Thursday, May 2nd.

G1 Therapeutics Trading Down 4.9 %

Shares of GTHX opened at $4.27 on Monday. The firm has a market cap of $223.24 million, a P/E ratio of -6.89 and a beta of 1.71. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.94 and a quick ratio of 2.55. G1 Therapeutics has a 1 year low of $1.08 and a 1 year high of $5.00. The company has a 50 day simple moving average of $3.98 and a two-hundred day simple moving average of $3.13.

Hedge Funds Weigh In On G1 Therapeutics

Large investors have recently made changes to their positions in the company. abrdn plc purchased a new stake in G1 Therapeutics in the 4th quarter worth about $1,293,000. Raymond James & Associates lifted its stake in shares of G1 Therapeutics by 16.9% during the 3rd quarter. Raymond James & Associates now owns 925,776 shares of the company’s stock worth $1,333,000 after acquiring an additional 133,662 shares during the last quarter. Acadian Asset Management LLC purchased a new position in G1 Therapeutics during the 3rd quarter valued at $189,000. FinTrust Capital Advisors LLC grew its position in G1 Therapeutics by 154,946.2% in the 4th quarter. FinTrust Capital Advisors LLC now owns 100,780 shares of the company’s stock valued at $307,000 after acquiring an additional 100,715 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in G1 Therapeutics by 68.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock worth $294,000 after purchasing an additional 82,879 shares during the period. 24.21% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at G1 Therapeutics

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $4.62, for a total transaction of $132,132.00. Following the sale, the insider now directly owns 169,938 shares in the company, valued at $785,113.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 8.23% of the company’s stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.